In this post-hoc analysis, we tested the hypothesis that treatment with the xanthine oxidase inhibitor (febuxostat) would lower serum TNFR levels, and early change in circulating TNFR levels predicts future eGFR decline in patients with CKD stage 3. Here, TNFRSF1A is linked to chronic kidney disease.